Is ADMS or RYLD a better dividend investment in 2026?

ADMS currently yields 24.33% with a 5% 5-year dividend growth rate. RYLD yields 12.39% with 5% growth. The better choice depends on your goal: ADMS offers higher current income.

What is the dividend yield difference between ADMS and RYLD?

ADMS has a forward dividend yield of 24.33% ($2.00/share annually). RYLD yields 12.39% ($1.81/share annually). The yield gap is 11.94 percentage points.

Home › Compare › ADMS vs RYLD

ADMS vs RYLD: Dividend Comparison 2026

ADMS yields 24.33% · RYLD yields 12.39%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ADMS wins by $49.6K in total portfolio value

INVESTMENT

TIME HORIZON10 years

ADMS

● Live price

24.33%

Share price

$8.22

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$94.9K

Annual income

$10,445.94

Full ADMS calculator →

RYLD

● Live price

12.39%

Share price

$14.64

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$45.3K

Annual income

$2,682.98

Full RYLD calculator →

Portfolio growth — ADMS vs RYLD

📍 ADMS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ADMS	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ADMS + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ADMS pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADMS

Annual income on $10K today (after 15% tax)

$2,068.13/yr

After 10yr DRIP, annual income (after tax)

$8,879.05/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,053.44/yr

After 10yr DRIP, annual income (after tax)

$2,280.53/yr

At 15% tax rate, ADMS beats the other by $6,598.52/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADMS + RYLD for your $10,000?

ADMS: 50%RYLD: 50%

100% RYLD50/50100% ADMS

Portfolio after 10yr

$70.1K

Annual income

$6,564.46/yr

Blended yield

9.37%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADMS right now

ADMS

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

RYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADMS buys

RYLD buys

No recent congressional trades found for ADMS or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricADMSRYLD

Forward yield	24.33% ✓	12.39%
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$94.9K ✓	$45.3K
Annual income after 10y	$10,445.94 ✓	$2,682.98
Total dividends collected	$59.3K ✓	$19.4K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: ADMS vs RYLD ($10,000, DRIP)

Year	ADMS Portfolio	ADMS Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$13,133	$2,433.09	$11,939	$1,239.34	+$1.2K → ADMS
2	$17,039	$2,986.35	$14,158	$1,382.89	+$2.9K → ADMS
3	$21,852	$3,621.00	$16,682	$1,532.59	+$5.2K → ADMS
4	$27,722	$4,340.18	$19,537	$1,687.64	+$8.2K → ADMS
5	$34,809	$5,145.80	$22,752	$1,847.20	+$12.1K → ADMS
6	$43,284	$6,038.47	$26,355	$2,010.43	+$16.9K → ADMS
7	$53,331	$7,017.47	$30,376	$2,176.45	+$23.0K → ADMS
8	$65,145	$8,080.76	$34,847	$2,344.43	+$30.3K → ADMS
9	$78,930	$9,225.06	$39,800	$2,513.54	+$39.1K → ADMS
10	$94,901	$10,445.94	$45,269	$2,682.98	+$49.6K → ADMS

ADMS vs RYLD: Complete Analysis 2026

ADMS — Stock

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Full ADMS Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this ADMS vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADMS vs SCHD ADMS vs JEPI ADMS vs O ADMS vs KO ADMS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.